HC Wainwright Estimates LifeMD’s Q3 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of LifeMD in a research note issued on Friday, August 7th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.15) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for LifeMD’s Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.12) EPS.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of LifeMD in a research report on Tuesday, August 4th. Lake Street Capital set a $5.00 target price on LifeMD in a report on Thursday, August 6th. KeyCorp set a $5.00 target price on LifeMD and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Mizuho set a $7.00 price target on LifeMD in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, LifeMD currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

LifeMD Price Performance

LFMD stock opened at $3.32 on Monday. The firm has a market capitalization of $160.02 million, a P/E ratio of -66.39 and a beta of 2.02. LifeMD has a 52-week low of $2.56 and a 52-week high of $7.32. The company’s 50 day simple moving average is $4.23 and its 200-day simple moving average is $3.97.

Institutional Investors Weigh In On LifeMD

Institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its holdings in shares of LifeMD by 278.1% during the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after acquiring an additional 721,018 shares in the last quarter. Prescott Group Capital Management L.L.C. purchased a new stake in shares of LifeMD during the fourth quarter worth $2,344,000. Arrowstreet Capital Limited Partnership boosted its position in LifeMD by 1,767.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after purchasing an additional 411,651 shares during the last quarter. JPMorgan Chase & Co. boosted its position in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Finally, Whetstone Capital Advisors LLC grew its stake in LifeMD by 89.6% in the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock valued at $2,397,000 after purchasing an additional 332,269 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.